Stocktoria
PROCYON CORP PCYN
OTC · stock · Pharmaceutical Preparations · website · IPO 1996-12-11
PROCYON CORP financials (annual)
Bars are annual figures from 2017 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $4.7M | $4.8M | $4.7M | — | $4.3M | — | $4.2M | $4.0M | $4.0M |
| Gross profit | $3.9M | $3.6M | $3.5M | $3.4M | — | $3.2M | — | $3.0M | $2.9M | $2.7M |
| R&D expense | $30,100 | $30,600 | $30,000 | $30,900 | — | $23,093 | — | $33,140 | $41,747 | $31,298 |
| SG&A expense | $2.0M | $1.8M | $1.7M | $1.3M | — | $1.3M | — | $1.4M | $1.3M | $1.2M |
| Operating income | -$231,705 | -$97,381 | -$237,215 | $226,674 | — | $153,016 | — | $97,073 | $127,085 | $29,964 |
| Interest expense | — | — | $0 | $2,172 | — | $0 | — | $0 | $0 | $2,846 |
| Income tax | $169,858 | -$15,129 | -$25,621 | $39,444 | — | $48,407 | — | $72,089 | $383,368 | $16,608 |
| Net income | -$341,140 | -$50,245 | -$209,790 | $694,349 | $293,409 | $111,658 | $83,636 | $27,224 | -$255,727 | $12,378 |
| EPS (diluted) | $-0.04 | $-0.01 | $-0.03 | $0.08 | — | $0.01 | — | $0.00 | $-0.03 | $0.00 |
| Operating cash flow | -$61,251 | $145,466 | -$383,482 | $279,500 | -$19,056 | $198,772 | -$158,385 | $50,837 | $86,499 | $199,560 |
| Free cash flow | -$125,163 | -$34,672 | -$466,126 | $214,334 | -$29,083 | $175,728 | -$169,535 | $22,084 | $39,772 | $180,704 |
| Cash & equivalents | — | — | — | — | — | — | $96,630 | $290,287 | $270,313 | $173,173 |
| Inventory | $510,006 | $431,405 | $761,651 | $591,058 | $623,632 | $758,516 | $590,827 | $485,433 | $416,621 | $506,719 |
| Total assets | $3.2M | $3.6M | $3.8M | $4.3M | $3.0M | $2.8M | $2.6M | $2.4M | $2.4M | $2.7M |
| Total liabilities | $917,122 | $946,002 | $1.1M | $1.4M | $547,451 | $657,925 | — | $375,935 | $326,476 | $442,311 |
| Shareholders' equity | $2.3M | $2.6M | $2.7M | $2.9M | $2.5M | $2.2M | $2.1M | $2.1M | $2.0M | $2.3M |
Growth · year-over-year · Revenue CAGR 3.1%
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +6.4% | -3.2% | +2.6% | — | — | — | — | +4.3% | +0.2% | +16.3% |
| Net income growth | — | — | -130.2% | +136.6% | +162.8% | +33.5% | +207.2% | — | -2166.0% | -88.7% |
| EPS growth | — | — | -137.5% | — | — | — | — | — | — | -100.0% |
| Free cash flow growth | — | — | -317.5% | — | -116.6% | — | -867.7% | -44.5% | -78.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2024-06-30. Facts plus Stocktoria's own computed scores — not investment advice.